Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| NeRRe Therapeutics | 2021 | Series B | $27.6M | Stevenage |
| Oxular | 2021 | Series B | $37.0M | Oxford |
| CoviCept Therapeutics | 2021 | Seed | $2.3M | San Diego |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 76 | NeRRe Therapeutics | Series B | $27.6M | Stevenage, United Kingdom |
| 77 | Oxular | Series B | $37.0M | Oxford, United Kingdom |
| 78 | CoviCept Therapeutics | Seed | $2.3M | San Diego, United States |
| 79 | OMEICOS Therapeutics | Series C | $19.4M | Berlin, Germany |
| 80 | Gotham Therapeutics | Series A | $54.0M | New York, United States |
| 81 | KaNDy Therapeutics | Series C | $32.6M | Stevenage, United Kingdom |
| 82 | Escalier Biosciences | Series B | $19.0M | Encinitas, United States |
| 83 | Prexton Therapeutics | Series B | $31.1M | Plan-les-ouates, Switzerland |
| 84 | Rigontec | Series A | $16.9M | Martinsried, Germany |
| 85 | Akarna Therapeutics | Series B | $15.0M | Cambridge, United States |
NeRRe Therapeutics is a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists.
Oxular is a medical device startup dedicated to revolutionizing the way we measure ocular surface topography.
CoviCept Therapeutics is focused on the development of a small molecule that inhibits the replication and spread of RNA viruses.
OMEICOS Therapeutics is developing a novell molecule utilizing a new Mode of Action for the treatment and prevention of atrial fibrillation.
Gotham Therapeutics is discovering a novel drug class targeting the epitranscriptomics machinery.
KaNDy Therapeutics is a clinical-stage company focused on optimizing the potential of NT-814.
Escalier Biosciences BV is a privately held biopharmaceutical company.
Prexton Therapeutics has the mission to develop innovative drugs to improve the quality of life.
Rigontec is the leader in RIG-I targeting RNA therapeutics developing novel immuno-oncology treatment options.
At Akarna, our mission is to develop best-in-class treatments for NASH and other chronic liver diseases
Ario Pharma is focused on the development of drugs for the treatment of respiratory indications.
Dezima Pharma develops protein-based compounds for treatment of cardiovascular disease related to dyslipidemia.
Amakem is a kinase platform company developing therapeutics for the treatment of serious eye conditions.
gIcare Pharma is a Canada-based company that develops novel gastrointestinal drugs for unmet medical needs.
Forbion Capital Partners has invested in 89 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Forbion Capital Partners's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 8 different industry categories.
Among tracked funding rounds, Gotham Therapeutics received $54.0M in a Series A round. Forbion Capital Partners's total known invested capital is $6.2B.
Forbion Capital Partners's average investment size is $87.8M across its portfolio of 89 companies.
Recent Forbion Capital Partners portfolio additions include NeRRe Therapeutics, Oxular, CoviCept Therapeutics. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors